Skip to main content
NewslettersWatchlist

Curevac N.V.(CVAC-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.34
Day High2.59
Open:2.48
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
ACCESSWIRE
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
ACCESSWIRE
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
Motley Fool
Why CureVac Stock Plunged Today
ACCESSWIRE
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
MarketBeat
3 Stocks to Buy For the COVID Resurgence
ACCESSWIRE
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
ACCESSWIRE
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
ACCESSWIRE
CureVac Announces Update to the Management Team
ACCESSWIRE
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
Motley Fool
Why Shares of CureVac Jumped This Week
Motley Fool
Why CureVac Stock Leaped 12% Higher Today
ACCESSWIRE
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
ACCESSWIRE
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
ACCESSWIRE
CureVac Announces Voting Results of General Meeting
ACCESSWIRE
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
ACCESSWIRE
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
ACCESSWIRE
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
ACCESSWIRE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
ACCESSWIRE
CureVac Announces Voting Results of Extraordinary General Meeting
ACCESSWIRE
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
ACCESSWIRE
CureVac Announces Proposed Public Offering of Common Shares
ACCESSWIRE
CureVac Welcomes Myriam Mendila as New Chief Development Officer
ACCESSWIRE
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)
ACCESSWIRE
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
Barchart
Pre-Market Brief: Stocks Mostly Lower As Recession Worries Outweigh Cooler Inflation Data
Motley Fool
Why CureVac's Shares Jumped on Tuesday
Barchart
Unusual Options Activity Booms for Novavax (NVAX) But Concerns Remain
Barchart
Unusual Options Activity Confirms Optimism for CureVac (CVAC) Amid ‘Tripledemic’
Barchart
Pre-Market Brief: Stocks Move Higher As China Reopening Boosts Sentiment, Fed Fears Ease
ACCESSWIRE
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
ACCESSWIRE
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

Profile

CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.